orelabrutinib maintenance
Phase 2Small molecule
orelabrutinib maintenance is one of 4 small molecule programs targeting Autologous Hematopoietic Stem Cell Transplantation. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Autologous Hematopoietic Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 2
Mozobil
GGenzyme, a Sanofi Company
Phase 2
orelabrutinib maintenance
RRuijin Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for orelabrutinib maintenance. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRuijin Hospital